Alterations in p53 and p16INK4 expression and telomere length during spontaneous immortalization of Li-Fraumeni syndrome fibroblasts. 1995

E M Rogan, and T M Bryan, and B Hukku, and K Maclean, and A C Chang, and E L Moy, and A Englezou, and S G Warneford, and L Dalla-Pozza, and R R Reddel
Cancer Research Group, Children's Medical Research Institute, Westmead, Sydney, New South Wales, Australia.

Normal cells have a strictly limited growth potential and senesce after a defined number of population doublings (PDs). In contrast, tumor cells often exhibit an apparently unlimited proliferative potential and are termed immortalized. Although spontaneous immortalization of normal human cells in vitro is an extremely rare event, we observed this in fibroblasts from an affected member of a Li-Fraumeni syndrome kindred. The fibroblasts were heterozygous for a p53 mutation and underwent senescence as expected at PD 40. In four separate senescent cultures (A to D), there were cells that eventually recommenced proliferation. This was associated with aneuploidy in all four cultures and either loss (cultures A, C, and D) or mutation (culture B) of the wild-type (wt) p53 allele. Loss of wt p53 function was insufficient for immortalization, since cultures A, B, and D subsequently entered crisis from which they did not escape. Culture C has continued proliferating beyond 400 PDs and thus appears to be immortalized. In contrast to the other cultures, the immortalized cells have no detectable p16INK4 protein. A culture that had a limited extension of proliferative potential exhibited a progressive decrease in telomere length with increasing PD. In the culture that subsequently became immortalized, the same trend occurred until PD 73, after which there was a significant increase in the amount of telomeric DNA, despite the absence of telomerase activity. Immortalization of these cells thus appears to be associated with loss of wt p53 and p16INK4 expression and a novel mechanism for the elongation of telomeres.

UI MeSH Term Description Entries
D007621 Karyotyping Mapping of the KARYOTYPE of a cell. Karyotype Analysis Methods,Analysis Method, Karyotype,Analysis Methods, Karyotype,Karyotype Analysis Method,Karyotypings,Method, Karyotype Analysis,Methods, Karyotype Analysis
D008819 Mice, Nude Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses. Athymic Mice,Mice, Athymic,Nude Mice,Mouse, Athymic,Mouse, Nude,Athymic Mouse,Nude Mouse
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D009374 Neoplasms, Experimental Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms. Experimental Neoplasms,Experimental Neoplasm,Neoplasm, Experimental
D011003 Ploidies The degree of replication of the chromosome set in the karyotype. Ploidy
D002352 Carrier Proteins Proteins that bind or transport specific substances in the blood, within the cell, or across cell membranes. Binding Proteins,Carrier Protein,Transport Protein,Transport Proteins,Binding Protein,Protein, Carrier,Proteins, Carrier
D002471 Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill. Neoplastic Transformation, Cell,Neoplastic Cell Transformation,Transformation, Neoplastic Cell,Tumorigenic Transformation,Cell Neoplastic Transformation,Cell Neoplastic Transformations,Cell Transformations, Neoplastic,Neoplastic Cell Transformations,Neoplastic Transformations, Cell,Transformation, Cell Neoplastic,Transformation, Tumorigenic,Transformations, Cell Neoplastic,Transformations, Neoplastic Cell,Transformations, Tumorigenic,Tumorigenic Transformations
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D002869 Chromosome Aberrations Abnormal number or structure of chromosomes. Chromosome aberrations may result in CHROMOSOME DISORDERS. Autosome Abnormalities,Cytogenetic Aberrations,Abnormalities, Autosome,Abnormalities, Chromosomal,Abnormalities, Chromosome,Chromosomal Aberrations,Chromosome Abnormalities,Cytogenetic Abnormalities,Aberration, Chromosomal,Aberration, Chromosome,Aberration, Cytogenetic,Aberrations, Chromosomal,Aberrations, Chromosome,Aberrations, Cytogenetic,Abnormalities, Cytogenetic,Abnormality, Autosome,Abnormality, Chromosomal,Abnormality, Chromosome,Abnormality, Cytogenetic,Autosome Abnormality,Chromosomal Aberration,Chromosomal Abnormalities,Chromosomal Abnormality,Chromosome Aberration,Chromosome Abnormality,Cytogenetic Aberration,Cytogenetic Abnormality

Related Publications

E M Rogan, and T M Bryan, and B Hukku, and K Maclean, and A C Chang, and E L Moy, and A Englezou, and S G Warneford, and L Dalla-Pozza, and R R Reddel
August 1998, Oncogene,
E M Rogan, and T M Bryan, and B Hukku, and K Maclean, and A C Chang, and E L Moy, and A Englezou, and S G Warneford, and L Dalla-Pozza, and R R Reddel
December 1990, Cancer research,
E M Rogan, and T M Bryan, and B Hukku, and K Maclean, and A C Chang, and E L Moy, and A Englezou, and S G Warneford, and L Dalla-Pozza, and R R Reddel
April 1993, Cancer genetics and cytogenetics,
E M Rogan, and T M Bryan, and B Hukku, and K Maclean, and A C Chang, and E L Moy, and A Englezou, and S G Warneford, and L Dalla-Pozza, and R R Reddel
December 1994, Biochimica et biophysica acta,
E M Rogan, and T M Bryan, and B Hukku, and K Maclean, and A C Chang, and E L Moy, and A Englezou, and S G Warneford, and L Dalla-Pozza, and R R Reddel
January 1995, Molecular and cellular biology,
E M Rogan, and T M Bryan, and B Hukku, and K Maclean, and A C Chang, and E L Moy, and A Englezou, and S G Warneford, and L Dalla-Pozza, and R R Reddel
January 1995, Carcinogenesis,
E M Rogan, and T M Bryan, and B Hukku, and K Maclean, and A C Chang, and E L Moy, and A Englezou, and S G Warneford, and L Dalla-Pozza, and R R Reddel
March 1992, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
E M Rogan, and T M Bryan, and B Hukku, and K Maclean, and A C Chang, and E L Moy, and A Englezou, and S G Warneford, and L Dalla-Pozza, and R R Reddel
December 1991, Lancet (London, England),
E M Rogan, and T M Bryan, and B Hukku, and K Maclean, and A C Chang, and E L Moy, and A Englezou, and S G Warneford, and L Dalla-Pozza, and R R Reddel
February 1993, Science (New York, N.Y.),
E M Rogan, and T M Bryan, and B Hukku, and K Maclean, and A C Chang, and E L Moy, and A Englezou, and S G Warneford, and L Dalla-Pozza, and R R Reddel
July 2005, Cell cycle (Georgetown, Tex.),
Copied contents to your clipboard!